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ABSTRACT
Cytomegalovirus (CMV) pneumonia is a life-threatening infection in patients with haematological
malignancies (HMs) or in haematopoietic stem cell transplant (HSCT) recipients. To assess the incidence
and risk factors for developing fatal CMV pneumonia in these patients, a case–control study based on
999 autopsies was performed at The University of Texas M. D. Anderson Cancer Center, Houston, Texas
(January 1990 to December 2004). Twenty-ﬁve cases (patients who died with CMV pneumonia) were
matched with 34 controls (patients who died without CMV pneumonia) by type of HM or HSCT, year of
autopsy, age and gender. The incidence of CMV pneumonia declined between January 1990 to June
⁄ 1997 and July 1997 to December 2004 (CMV pneumonia rates were 22 ⁄ 620 and 3 ⁄ 379 autopsies,
respectively; p 0.006). Logistic regression analysis identiﬁed complete remission and sustained
lymphopenia as independent predictors of CMV pneumonia (all p <0.05). The incidence of fatal CMV
pneumonia has decreased over the last 15 years, which might reﬂect earlier diagnosis or the use of pre-
emptive therapy or more effective preventive strategies. Complete remission of an HM does not
preclude the development of CMV pneumonia among patients with prolonged lymphopenia.
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INTRODUCTION
Cytomegalovirus (CMV) pneumonia is a fre-
quently fatal infection in patients with haemato-
logical malignancies (HMs) and in those
undergoing haematopoietic stem cell transplanta-
tion (HSCT); the disease-speciﬁc mortality rate
varies from 30% in lymphoma patients, to 57% in
those with leukaemia and up to 90% in those who
have undergone HSCT [1–5]. Deﬁnitive diagnosis
of CMV pneumonia relies on the detection of the
virus in lung tissue; however, lung biopsies are
rarely performed in patients with cancer because
of themorbidity (e.g. bleeding) associatedwith this
procedure [6,7]. Thus, studies of histopathologi-
cally proven CMV pneumonia in cancer patients
have been limited. The serious consequences of
CMV pneumonia in such patients, however, make
it vitally important that we better understand
and characterize the risk factors for infection.
The incidence of CMV disease revealed after
autopsy of immunocompromised hosts ranges
from 0.3% to 51% [8]. Data from autopsies of
cancer patients who were not HSCT recipients at
The University of Texas M.D. Anderson Cancer
Center (MDACC) from January 1964 through
December 1990 showed an increase in the inci-
dence of CMV pneumonia [9]. Given this poten-
tially large source of patient data, a case–control
study of patients who had been autopsied at
MDACC was designed, speciﬁcally to determine
the incidence of, and the risk factors for, fatal
CMV pneumonia in patients with HMs, including
HSCT recipients.
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PATIENTS AND METHODS
The autopsy records of all patients in the MDACC autopsy
registry who were reported to have died between January 1990
and December 2004 (n = 999) were reviewed. Patients with
HMs or who were HSCT recipients were included in the study
and categorized according to the absence (controls) or pres-
ence (cases) of CMV pneumonia at autopsy. The 25 cases were
matched with 34 controls, primarily by type of HM or prior
HSCT receipt (100% of cases) and secondarily by year of
autopsy (85% of cases), patient age (74% of cases) and patient
gender (74% of cases). Information on demographics, type of
HM or HSCT, comorbidities (e.g. chronic lung disease or renal
failure, autoimmune disorders, diabetes mellitus or hypo-
gammaglobulinaemia), chemotherapy and corticosteroid treat-
ment, disseminated CMV disease, concomitant infections,
clinical and radiological signs of CMV pneumonia and
antiviral treatment, were collected from the patients’ medical
records. The cause of death recorded in each autopsy report
was noted. Human immunodeﬁciency virus-infected patients
were included. Patients with solid tumours, however, were
excluded. The study was approved by the MDACC institu-
tional review board.
Deﬁnitions
Autopsy-proven CMV pneumonia was deﬁned as the presence
of CMV infection in lung tissue samples identiﬁed by charac-
teristic intranuclear or intracytoplasmic viral inclusions with
surrounding necrosis, inﬂammation or both. For most
patients, sections of the lungs, lymph nodes, liver, spleen,
adrenal glands and other tissues indicated to be of interest in
the autopsy report were examined. The results of cultures
performed at the time of the autopsies were obtained from
records available in the microbiology laboratory. Culture
identiﬁcation tests for CMV (shell vial or conventional viral
cultures) were performed on lung tissue samples of some
patients as previously described [10]. Also, CMV antigena-
emia—detection of the viral protein CMV pp65 in white
blood cells—was performed in a small subset of patients.
Neutropenia was deﬁned as a neutrophil count of <500 ⁄mm3.
Lymphopenia was deﬁned as a lymphocyte count of
<1000 ⁄mm3.
Therapy
Therapy for CMV pneumonia consisted of intravenous ganci-
clovir (5 mg ⁄ kg every 12 h) with or without intravenous
immunoglobulin (500 mg ⁄kg every other day). Foscarnet
(60 mg ⁄ kg intravenously every 8 h) was substituted for ganci-
clovir in patients who experienced severe myelosuppression
during ganciclovir therapy. The ganciclovir and foscarnet
doses were adjusted as needed, depending on the creatinine
clearance.
Statistical analysis
Case and control data were compared to identify possible
predictors of the development of CMV pneumonia. Univariate
analysis using Fisher’s exact test was then used to assess the
signiﬁcance of differences between the two groups. Variables
with p <0.1 and those found to be clinically relevant according
to univariate analysis were then subjected to multivariate
logistic regression analysis. Multiple logistic regression was
used to assess the predictors of development of CMV pneu-
monia in cases and controls, to determine which factors were
independent predictors of CMV pneumonia. All data were
analysed using SAS software (SAS Institute, Cary, NC, USA)
and Epi Info (version 3.2.2; CDC, Atlanta, GA, USA). Two-
tailed p-values of <0.05 were considered to be statistically
signiﬁcant.
RESULTS
Incidence
From January 1990 through December 2004, 999
autopsies were performed at MDACC. CMV
pneumonia was diagnosed after histopathological
examination in 25 patients. The total incidence of
CMV pneumonia at autopsy was 3% (25 of 999
autopsies), with a signiﬁcant decline between the
periods of January 1990 through June 1997 and
July 1997 through December 2004 (22 of 620
(3.5%) and three of 379 (0. 8%) autopsies, respec-
tively; p 0.006). The autopsy rate also decreased
signiﬁcantly between these two periods (620 of
4855 (13%) and 379 of 5001 (8%) deaths, respec-
tively; p 0.0001).
Patients
The characteristics of patients with CMV pneumo-
nia are given in Table 1. Most of the cases of
pneumonia occurred in HSCT recipients (68%,
mainly allogeneic) and lymphoma patients (20%,
mainly non-Hodgkin lymphoma). No patient had
underlying acute leukaemia. Three patients were
infected with human immunodeﬁciency virus.
Twenty of the 25 patients (80%) had received
chemotherapy and 17 patients (68%) had been
treatedwith corticosteroids (68%)within 6 months
prior to autopsy. The majority of patients required
admission to the intensive-care unit with respira-
tory and circulatory support (Table 1). Themedian
number of days between the onset of ﬁrst CMV-
related symptoms and HSCT was 118 (Table 1).
CMV pneumonia was diagnosed ante mortem in
16 of 25 patients (64%) by detection of pulmonary
inﬁltrate and identiﬁcation of CMV in the lower
respiratory tract (12 patients) or other sites (four
patients). CMV pneumonia was clinically sus-
pected before their death in 15 of these 16
patients. The lower respiratory tract samples were
obtained by means of bronchoalveolar lavage
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alone in seven patients; bronchoalveolar lavage
plus nasal wash, sputum, transtracheal aspirate,
sputum plus nasal wash and lung tissue biopsy
were each used to obtain samples from one
patient. The extrapulmonary samples positive
for CMV were buffy coat plus urine in two
patients, whole blood in one patient, and a skin
biopsy specimen in one patient.
Fungal pneumonia was the presumptive diag-
nosis in seven of the 25 patients (28%). Dissem-
inated CMV disease was detected in 12 of the 24
cases (50%) in which autopsy was not limited to
the chest. Of these 12 patients with extrapulmo-
nary CMV disease, four (33%) had infection at
one site, seven (58%) at two sites, and one (8%) at
three sites besides the lungs. Speciﬁcally, in these
12 patients with extrapulmonary involvement,
CMV infected the adrenal glands in ten patients
(83%), the kidneys in four (33%), the gastrointes-
tinal tract in four (33%), the liver in two (17%),
and the skin in one (8%). Postmortem eye
examinations are not routinely performed at
MDACC. When compared to patients with CMV
pneumonia alone, those with disseminated dis-
eases had more frequently received a high
accumulative corticosteroid dose (‡600-mg accu-
mulative dose of prednisone equivalent) (one
of 12 (8%) and ﬁve of 12 (42%), p 0.1). No
case of disseminated CMV disease occurred after
1995.
CMV was microbiologically conﬁrmed by viral
cultures in six of nine (67%) patients studied.
Detection of CMV antigenaemia preceded the
postmortem diagnosis of CMV pneumonia in four
of ﬁve patients (80%) tested. In four of these ﬁve
cases, autopsy was not limited to the chest, but
none of the patients showed extrapulmonary
infection. The median duration of antigenaemia
was 30 days (range, 19–41 days). The median
number of CMV-infected cells per 106 white
blood cells was 50 (range, 1–1061).
CMV was the only identiﬁable pathogen at
autopsy in 11 of the 25 case patients (44%), with
fungi being the most common co-pathogens
(Table 2).
Risk factors
When compared to controls, more CMV-infected
patients had complete remission of HM (60% vs.
12%), had sustained (>3 months) lymphopenia at
the time of death (55% vs. 15%), and had herpes
simplex virus co-infection <1 month before
autopsy (36% vs. 6%) (all p <0.05) by univariate
analysis.
There was a trend towards radiation therapy
(e.g. total body irradiation, localized radiation)
and receipt of cyclosporine being more common
in case patients than in controls (56% vs. 32%;
p 0.07, and 15% vs. 0%, p 0.06, respectively).
Multiple logistic regression identiﬁed complete
remission and long duration of lymphopenia
as independent factors associated with fatal
CMV pneumonia (all p <0.05) (Table 2). There
was a trend towards radiation therapy being
more common in case patients than in controls
(p 0.09).
The signiﬁcant predictive role of lymphocyte
recovery among patients, with or without CMV
pneumonia, is shown in Fig. 1. The occurrence of
Pneumocystis jiroveci and invasive mould co-infec-
tion was comparable in both groups (Table 2).
Likewise, comparable proportions of controls and
case patients received either chemotherapy or
Table 1. Characteristics of patients with cytomegalovirus
(CMV) pneumonia at autopsy, who had haematological
malignancies, or who had undergone haematopoietic stem
cell transplantation
Characteristic No. (%)*
Sex, male ⁄ female 18 ⁄ 7
Median age, years (range) 43 (15–76)
Underlying condition
HSCT 17 ⁄ 25 (68)
Allogeneic 15 ⁄ 17 (88)
Autologous 2 ⁄ 17 (12)
Lymphoma 5 ⁄ 25 (20)
Hodgkin 1 ⁄ 25 (4)
Non-Hodgkin 4 ⁄ 25 (16)
Leukaemia 3 ⁄ 25 (12)
Chronic myeloid 1 ⁄ 3 (33)
Chronic lymphocytic 2 ⁄ 3 (66)
HM in complete remission status 15 ⁄ 25 (60)
Previously relapsed HM 17 ⁄ 25 (68)
Median days between ﬁrst CMV
symptoms and HSCT (range)
118 (0–541)
Duration of symptoms (days) 20 (2–71)
Admission to ICU 19 ⁄ 25 (76)
Mechanical ventilation 18 ⁄ 25 (72)
Need for vasopressors 18 ⁄ 25 (72)
Median Apache II score (range) 12 (10–19)
Median absolute neutrophil counta 1850 (100–17 590)
Neutropeniaa 4 ⁄ 25 (16)
Median duration of neutropenia (days) 10 (3–22)
Median absolute lymphocyte counta (range) 200 (0–3300)
Lymphopenia <1000 cells ⁄mLa 20 ⁄ 25 (80)
Median duration of lymphopeniaa (days) 93 (12–717)
Antemortem diagnosis of CMV pneumoniab 16 ⁄ 25 (64)
Median duration of CMV diagnosis before deathb (days) 22 (2–93)
Disseminated CMV infection 12 ⁄ 25 (48)
Treatment for CMV pneumonia 15 ⁄ 25 (60)
HSCT, haematopoietic stem cell transplantation; ICU, intensive-care unit; HM,
haematological malignancy.
aAt diagnosis of infection.
bExcluding cases with CMV antigenaemia.
*Number reﬂects the number of patients, except as otherwise stated.
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immunosuppressive treatment within 6 months
of autopsy (Table 2). However, the last cycle of
chemotherapy was administered closer to the
date of death in controls than in patients with
CMV pneumonia (median, 29 vs. 80 days,
p <0.01).
Therapy and cause of death
Fifteen of the 25 case patients (60%) received
CMV-directed antiviral therapy (Table 1). Nine of
them (60%) received single-agent therapy with
either ganciclovir (eight patients (89%)) or foscar-
net (one patient (11%)), and the other six received
the combination of ganciclovir and foscarnet. The
median duration of antiviral therapy was 9 days
(range, 1–31 days). Immunoglobulin was given
intravenously to 11 of the 15 antiviral-treated
patients; no patient received immunoglobulin
alone.
Ten case patients did not receive antiviral
therapy. All of them were not treated because
the diagnosis of CMV pneumonia was not clini-
cally suspected ante mortem and became known
only after death. In two of these ten patients, CMV
pneumonia was clinically suspected ante mortem,
Table 2. Risk factors for progres-
sion to fatal cytomegalovirus pneu-
monia in cancer patients who had
haematological malignancies (HMs)
or who had undergone haematopoi-
etic stem cell transplantion (HSCT)
Characteristics
Cases
(n = 25)
Controls
(n = 34)
p-value
(Fisher’s
exact test)
p-value
(multiple logistic
regression)
Sex, male ⁄ female 18 ⁄ 7 23 ⁄ 11 0.7
Median age, years (range) 43 (15–76) 44 (23–71) 0.7
Underlying condition, no. (%)
HSCT 17 ⁄ 25 (68) 26 ⁄ 34 (76) 0.4
Leukaemia 3 ⁄ 25 (12) 4 ⁄ 34 (12) 1.0
Lymphoma 5 ⁄ 25 (20) 4 ⁄ 34 (12) 0.4
Complete remission status 15 ⁄ 25 (60) 4 ⁄ 34 (12) 0.0001 0.008
Comorbidities 5 ⁄ 25 (20) 12 ⁄ 34 (35) 0.2
HIV infection 3 ⁄ 25 (12) 0 ⁄ 34 (0) 0.07 0.9
Corticosteroidsa 17 ⁄ 25 (68) 28 ⁄ 34 (82) 0.2
‡600-mg accumulative dose of
prednisone equivalent
6 ⁄ 17 (35) 5 ⁄ 28 (18) 0.2
Radiotherapy 14 ⁄ 25 (56) 11 ⁄ 34 (32) 0.07 0.09
Chemotherapy ⁄ immunosuppressorsa 20 ⁄ 25 (80) 28 ⁄ 34 (82) 1.0
Fludarabine 3 ⁄ 20 (15) 5 ⁄ 28 (18) 1.0 0.9
Cyclosporine 3 ⁄ 20 (15) 0 ⁄ 28 (0) 0.06
Neutropenia 4 ⁄ 25 (16) 8 ⁄ 34 (24) 0.4
Lymphopenia, no. (%) 20 ⁄ 25 (80) 33 ⁄ 34 (97) 0.07
Median duration of lymphopenia, days (range) 93 (12–717) 35 (1–492) 0.0006
More than 3 months of lymphopenia 11 ⁄ 20 (55) 5 ⁄ 33 (15) 0.002 0.04
Pulmonary inﬁltrate present 24 ⁄ 25 (96) 24 ⁄ 34 (71) 0.01
Alveolar inﬁltrate 4 ⁄ 24 (17) 16 ⁄ 24 (67) 0.0005
Co-infections within 1 month of autopsy 22 ⁄ 25 (88) 26 ⁄ 34 (76) 0.3
Fungal co-infectionsb 6 ⁄ 25 (24) 13 ⁄ 34 (38) 0.2
Pneumocystis jiroveci 1 ⁄ 25 (4) 0 ⁄ 34 (0) 0.4
Other moulds 3 ⁄ 25 (12) 3 ⁄ 34 (9) 0.6
Bacterial co-infectionsb 15 ⁄ 25 (60) 19 ⁄ 34 (56) 0.7
Viral co-infectionsb,c 9 ⁄ 25 (36) 2 ⁄ 34 (6) 0.005
Herpes simplex virus 7 ⁄ 25 (28) 2 ⁄ 34 (6) 0.02 0.1
Co-infections at autopsy 14 ⁄ 25 (56) 23 ⁄ 34 (68) 0.3
Fungal co-infectionsb 10 ⁄ 25 (40) 16 ⁄ 34 (47) 0.5
Pneumocystis jiroveci 2 ⁄ 25 (8) 0 ⁄ 34 (0) 0.1
Other moulds 6 ⁄ 25 (24) 9 ⁄ 34 (27) 0.8
Bacterial co-infectionsb 5 ⁄ 25 (20) 11 ⁄ 34 (32) 0.2
Viral co-infectionsb,c 1 ⁄ 25 (4) 2 ⁄ 34 (6) 1.0
HIV, human immunodeﬁciency virus.
aWithin 6 months of autopsy.
bPatients may have more than one co-infection.
cOther than CMV.
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Fig. 1. Kaplan–Meier survival curves for patients with
haematological malignancies showing the time to lympho-
cyte recovery among patients with (dotted line) or without
(solid line) cytomegalovirus pneumonia at autopsy
(p 0.0024).
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but initiation of CMV therapy was deferred for
microbiological conﬁrmation of infection.
All 25 case patients died from CMV pneumonia
and other contributory causes of death, including
co-infections (14 patients), active HM (three
patients), and other causes (three patients).
Among controls, the causes of death included
infections (23 patients), active HM (18 patients),
and other causes (four patients). Autopsy reports
commonly listed more than one cause of death for
both case patients and controls.
DISCUSSION
This autopsy series shows that the incidence of
fatal CMV pneumonia is decreasing; the current
data were in contrast to autopsy data concerning
cancer patients who were not HSCT recipients at
MDACC from 1964 through 1990, which showed
an overall increase in the incidence of CMV
pneumonia [9]. Several reasons may account for
this difference. First, the increased incidence
reported in the previous series was mainly attrib-
uted to an increase in the number of patients with
both solid tumours and CMV pneumonia [9].
Because this population was excluded from the
current analysis, the two studies are not fully
comparable. Second, the diagnosis of CMV pneu-
monia was not made until death in the majority of
patients (19 of 20 (95%)) autopsied in the previous
study, whereas CMV pneumonia was diagnosed
ante mortem in most cases in the current series,
probably reﬂecting the improved ability to detect
CMV pneumonia early, a critical step in its timely
treatment. Third, the decreased incidence of CMV
pneumonia over the last 15 years reﬂects the
development and use of more effective preventive
and therapeutic strategies. Finally, the decline in
the autopsy rate in recent years could also account
for the decrease in total numbers of CMV
pneumonias identiﬁed between July 1997 and
December 2004.
Autopsy series have revealed several risk
factors for CMV pneumonia, including, for
example, hypoalbuminaemia [11] and corticoste-
roid use [12,13]. Many factors in the present
study were not independent predictors of CMV
pneumonia but, rather, represent common con-
ditions or exposures in this patient population.
However, other predictors that may be used to
identify patients at risk of fatal infection were
recognized. Among these predictors, herpes sim-
plex virus infection ⁄ reactivation seemed to be a
marker of presumptive cellular immunosuppres-
sion preceding the onset of CMV pneumonia in
the study patients. In other autopsy series,
cutaneous herpetic lesions were clinically diag-
nosed in almost one-third of patients with
autopsy-proven CMV pneumonia [11]. In this
study, prolonged lymphopenia was an indepen-
dent predictor of fatal CMV pneumonia. Intact
cellular immune responses are critical in control-
ling acute CMV infection and, especially, in
preventing recrudescent viral infection and end-
organ disease [14]. Patients with delayed T-cell
reconstitution after HSCT are at increased risk of
infection [15]. Recovery of cytotoxic T-lympho-
cytes and of functionally active helper T-cells
are central in preventing CMV reactivation fol-
lowing HSCT [16,17]. In patients with HMs or
prior HSCT, peripheral blood lymphocyto-
penia was signiﬁcantly associated with serious
CMV pneumonia and may represent cancer-
and ⁄ or antineoplastic treatment-associated cellu-
lar dysfunction.
Current recommendations from the CDC state
that patients at risk of CMV disease after HSCT
should be placed on a CMV disease prevention
programme from the time of engraftment until
100 days after HSCT [18]. The same guidelines
indicate that no beneﬁt has been reported from
routine administration of prophylaxis to all HSCT
recipients at >100 days after HSCT, unless risk
factors for late CMV disease are present, includ-
ing allogeneic HSCT accompanied by chronic
graft-versus-host disease, corticosteroid use, low
CD4+ T-lymphocyte count counts, delay in high-
avidity anti-CMV antibody, and recipients of
matched unrelated or T-cell-depleted HSCTs
[18]. Whether the signiﬁcant number of high-risk
HSCT patients with late-onset CMV pneumonia
observed in this series is a consequence of ‘early
discontinuation’ (<100 days after HSCT) of pro-
phylactic ⁄pre-emptive strategies remains un-
known. In this study, the median onset of CMV
pneumonia was beyond day 100 after HSCT, and
sustained (>3 months) lymphopenia predicted
the development of such infection. Therefore, in
persistently lymphopenic patients, continuation
of CMV prophylaxis beyond 100 days after HSCT
(e.g. until lymphopenia resolves or improves), or
early detection of CMV with initiation of aggres-
sive therapeutic intervention, might prevent or
cure the pneumonia.
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Historical autopsy data for cancer patients,
with and without HMs, showed that CMV pneu-
monia was mainly observed in the setting of
uncontrolled malignancy [9]; in contrast, the HM
in 60% of the current patients was in remission.
The reason for this ﬁnding is unclear. Whether
this reﬂects the use of more targeted chemother-
apy over time, with a prolonged impact on
cellular immunity and ⁄ or the ability to prolong
a patient’s life long enough for them to experience
this complication, is unknown. In the subset of
leukaemia patients evaluated in this series, an-
other potential explanation is the occurrence of
the graft-versus-leukaemia response, which refers
to an immune-mediated anti-tumour effect fol-
lowing HSCT, and is not explained by pre-
transplant chemotherapy or radiation. In some
cases, the magnitude of this antileukaemia effect
can result in leukaemia cure [19,20]. In the pre-
anti-CMV drug era, a case–control study of
patients with CMV disease and acute leukaemia
showed pulmonary inﬁltration by leukaemia in
one of 13 patients with CMV disease (all of whom
had CMV lung infection) and six of 13 controls
(leukaemia patients who died without CMV
disease), indicating that at least localized
remission of leukaemia is common in patients
with fatal CMV pneumonia [13]. The use of
radiation or cyclosporine therapy was appar-
ently more common in patients with CMV
pneumonia than in controls. In agreement
with previous reports [9,11,21], several non-
HSCT-receiving case patients in this series had
lymphoma. Suppression of a host’s cellular
immune response, seen in lymphoma patients,
is the major underlying predisposing factor for
CMV disease [6].
Co-infection secondary to hyaline moulds (e.g.
Aspergillus spp., Fusarium spp.) has been reported
as a major contributor to death in patients with
CMV pneumonia [1,9], but among the study
patients, the presence of CMV in the lungs was
not associated with a higher incidence of co-
infections with pulmonary moulds as compared
to controls.
Almost half of the study patients with CMV
pneumonia had CMV involving other organs, but
no cases of disseminated CMV disease occurred
after 1995. The decline was probably due to an
increase in awareness of CMV infection, and thus
a low threshold for screening in recent years of
patients with HMs, and mainly of HSCT recipi-
ents, and to the availability of new diagnostic
techniques for detecting CMV infection during
the study period. Tests for CMV antigenaemia, for
example, became available in December 1995 at
MDACC, coinciding with the last detected case of
disseminated CMV infection.
This study is limited by both the small sample
of patients and its retrospective nature. As this
was an autopsy study, the true incidence of
CMV pneumonia may have been underesti-
mated. More speciﬁcally, CMV pneumonia was
deﬁned according to strict histopathological cri-
teria; however, ﬁnding CMV cytopathological
changes even when the infection is present may
be difﬁcult [12]. Several reports have shown that
virus isolation is more sensitive than histopa-
thology examination in establishing the presence
of CMV [8], probably because lung tissue is
sampled randomly during an autopsy [9]. It is
unlikely that the declining frequency of autop-
sies during the two time periods of interest
contributed to the lower incidence of CMV in the
later period. To our knowledge, the indications
for autopsy did not change over the study
period. Patients from different oncology services
(leukaemia, lymphoma, HSCT) were included in
this study during a 15-year span, and the use
and type of CMV prophylaxis was not standard-
ized across all of those conditions. Based on that,
information on CMV prophylaxis was not col-
lected. It is thus unclear whether CMV prophy-
laxis affected the incidence of CMV pneumonia
in the study patients. Because of the comparable
distributions of types of HM and HSCT among
patients in the two study groups, it seems
unlikely that CMV prophylaxis differed between
them.
In summary, the incidence of autopsy-proven
CMV pneumonia in cancer patients who have
HMs or who have undergone HSCT seems to be
decreasing, which might reﬂect improvements in
early diagnosis, leading to more timely treat-
ment, or advances in the prevention of such
infection over recent years. Extrapulmonary dis-
semination of CMV is now uncommon. Remis-
sion of an underlying HM does not preclude the
development of fatal CMV pneumonia, espe-
cially among patients with prolonged lymphope-
nia. Prophylactic ⁄pre-emptive strategies against
CMV pneumonia need to be optimized in per-
sistently lymphopenic patients with HMs or
prior HSCT.
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